Treatment guidelines have become an important element of medicine and psychiatry as a whole, and in 1994, the American Psychiatric Association (APA) issued the first treatment guidelines for bipolar disorder. Since then, a plethora of guidelines and treatment guidelines have emerged, reflecting an increased understanding of the subject area and a change in opinion and philosophy in the profession. Some guidelines have attempted to keep up with the latest evidence-based rationale, while others have incorporated more expert consensus. This article reviews three recently published (post-2010) guidelines for the treatment of bipolar depression: the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines, the Canadian Anxiety and Mood Disorders Treatment Network/International Society for Bipolar Disorder (CANMAT/ISBD) guidelines, and the National Institute for Health and Clinical Excellence (NICE) guidelines in the United Kingdom. ★WFSBP guideline Fluoxetine*: when olanzapine monotherapy is considered a placebo setting (Tohen et al. (2003).) The WFSBP guideline was updated in 2010 with an exhaustive classification of the various drugs based on the evidence-based pros and cons. The table above shows the treatments for evidence classification A and B: the only drug classified as A-1 is quetiapine, while olanzapine, lamotrigine, fluoxetine and valproate salt monotherapy, and olanzapine/fluoxetine combination (OFC), lamotrigine + lithium salt, and modafinil + existing therapy are classified as B-3. The WFSBP guidelines are perhaps the best balanced and most clinically useful of these guidelines to date.